A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Insomnia Disorders Clinical Trial

Official title:
A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder

Status Completed

Clinical Trial Summary

The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant) upon multiple (14 days) dose administration in participants with insomnia disorder.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Insomnia Disorders
Sleep Initiation and Maintenance Disorders

Clinical Trial Details

NCT number	NCT03375203
Study type	Interventional
Source	Janssen Research & Development, LLC
Contact
Status	Completed
Phase	Phase 2
Start date	November 23, 2017
Completion date	April 3, 2019

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03158025` - A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users	Phase 1